
## **Carmem Bonfim**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7344984/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival. Biology of Blood and Marrow Transplantation, 2007, 13, 1073-1082.	2.0	138
2	Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplantation, 2015, 50, 685-689.	1.3	128
3	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.	2.2	72
4	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 1-30.	0.6	71
5	Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 848-855.	2.0	67
6	Oral cancer in Fanconi anemia: Review of 121 cases. Critical Reviews in Oncology/Hematology, 2018, 125, 35-40.	2.0	58
7	Long-term Survival, Organ Function, and Malignancy after Hematopoietic Stem Cell Transplantation for Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1257-1263.	2.0	56
8	Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. Journal of Clinical Immunology, 2021, 41, 1479-1489.	2.0	56
9	The Salivary Microbiome and Oral Cancer Risk: A Pilot Study in Fanconi Anemia. Journal of Dental Research, 2017, 96, 292-299.	2.5	50
10	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 310-317.	2.0	50
11	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
12	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. Biology of Blood and Marrow Transplantation, 2017, 23, 1422-1428.	2.0	43
13	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	1.7	43
14	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biology of Blood and Marrow Transplantation, 2016, 22, 744-751.	2.0	41
15	Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplantation, 2017, 52, 671-677.	1.3	39
16	Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up. Molecular Genetics and Metabolism Reports, 2017, 12, 62-68.	0.4	39
17	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica, 2017, 102, 1291-1298.	1.7	38
18	Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency. Journal of Clinical Immunology, 2019, 39, 462-469.	2.0	34

#	Article	IF	CITATIONS
19	Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, 1923-1929.	2.0	34
20	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 726-735.	2.0	31
21	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. Haematologica, 2017, 102, 1112-1119.	1.7	30
22	Haematopoietic cell transplants in Latin America. Bone Marrow Transplantation, 2016, 51, 898-905.	1.3	29
23	Severe combined immunodeficiency in Brazil: management, prognosis, and BCC-associated complications. Journal of Investigational Allergology and Clinical Immunology, 2014, 24, 184-91.	0.6	28
24	Bone mineral density, vitamin D, and nutritional status of children submitted to hematopoietic stem cell transplantation. Nutrition, 2014, 30, 654-659.	1.1	27
25	Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 2311-2317.	2.0	26
26	Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia. Pediatric Hematology and Oncology, 2012, 29, 568-578.	0.3	25
27	Transplant results in adults with Fanconi anaemia. British Journal of Haematology, 2018, 180, 100-109.	1.2	25
28	Unrelated Hematopoietic Cell Transplantation in a Patient with Combined Immunodeficiency with Granulomatous Disease and Autoimmunity Secondary to RAG Deficiency. Journal of Clinical Immunology, 2016, 36, 725-732.	2.0	19
29	Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2487-2492.	2.0	19
30	Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 275-280.	2.0	18
31	Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone Marrow Transplantation, 2018, 53, 392-399.	1.3	16
32	Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. Hematology American Society of Hematology Education Program, 2020, 2020, 107-114.	0.9	16
33	Transplantation for Fanconi anaemia: lessons learned from Brazil. Lancet Haematology,the, 2022, 9, e228-e236.	2.2	15
34	Mouth self-examination as a screening tool for oral cancer in a high-risk group of patients with Fanconi anemia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, 440-446.	0.2	14
35	COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO). Bone Marrow Transplantation, 2022, 57, 453-459.	1.3	14
36	Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplantation, 2017, 52, 570-573.	1.3	13

#	Article	IF	CITATIONS
37	Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries. Journal of Clinical Immunology, 2018, 38, 917-926.	2.0	13
38	Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts. Transplantation and Cellular Therapy, 2021, 27, 782.e1-782.e7.	0.6	13
39	Adrenoleucodistrofia ligada ao X: correlação entre o escore de Loes e parâmetros do tensor de difusão. Radiologia Brasileira, 2014, 47, 342-349.	0.3	12
40	Access to oral care before hematopoietic stem cell transplantation: understand to improve. Supportive Care in Cancer, 2016, 24, 3307-3313.	1.0	11
41	Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation. Cytotherapy, 2014, 16, 976-989.	0.3	9
42	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
43	Mouth examination performance by children's parents and by adolescents in Fanconi anemia. Pediatric Blood and Cancer, 2017, 64, e26622.	0.8	9
44	Oral health status in children and adolescents with Fanconi anemia. Special Care in Dentistry, 2016, 36, 71-74.	0.4	8
45	A consensus document for the clinical management of invasive fungal diseases in pediatric patients with hematologic cancer and/or undergoing hematopoietic stem cell transplantation in Brazilian medical centers. Brazilian Journal of Infectious Diseases, 2019, 23, 395-409.	0.3	7
46	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 1747-1756.	2.0	7
47	Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012. Bone Marrow Transplantation, 2022, 57, 881-888.	1.3	7
48	Excellent Outcome for Fanconi Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) without Radiation: A Single Center Experience on 103 Patients. Biology of Blood and Marrow Transplantation, 2015, 21, S94.	2.0	6
49	High frequency of multiple HPV types detection in Fanconi anemia patients oral swabs. Transplant Infectious Disease, 2019, 21, e13030.	0.7	6
50	Self-perception of periodontal health status among individuals with Fanconi anemia. Hematology, Transfusion and Cell Therapy, 2021, 43, 453-458.	0.1	5
51	FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study. Bone Marrow Transplantation, 2021, 56, 285-288.	1.3	5
52	Body composition of Fanconi anemia patients after hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 318-324.	0.7	4
53	The impact of donorâ€specific anti―human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders. Hla, 2021, 97, 493-504.	0.4	4
54	Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. Bone Marrow Transplantation, 2021, 56, 3042-3048.	1.3	4

#	Article	IF	CITATIONS
55	Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation. European Journal of Pediatrics, 2022, 181, 715-723.	1.3	4
56	Analysis of baseline characteristics, disease burden and long-term follow-up of 167 patients with Paroxysmal Nocturnal Hemoglobinuria at a single center in Brazil. Blood Cells, Molecules, and Diseases, 2021, 92, 102605.	0.6	4
57	Ocular Manifestations in Patients With Fanconi Anemia: A Single Center Experience Including 106 Patients. Journal of Pediatrics, 2021, , .	0.9	4
58	Periodontal status of candidates for allogeneic hematopoietic stem cell transplantation. Special Care in Dentistry, 2017, 37, 187-193.	0.4	3
59	Short-term follow-up of the nutritional status of children with Fanconi anemia undergoing hematopoietic stem cell transplant. Supportive Care in Cancer, 2018, 26, 895-903.	1.0	3
60	Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. Pediatric Transplantation, 2020, 24, e13789.	0.5	3
61	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
62	Late chimerical status after bone marrow transplantation in severe aplastic anemia according to two different preparatory regimens. Hematology, Transfusion and Cell Therapy, 2018, 40, 112-119.	0.1	2
63	Investigation of MHC gamma block C4A and C4B polymorphisms in unrelated hematopoietic stem cell transplantation. Hematology, Transfusion and Cell Therapy, 2020, 42, 221-229.	0.1	2
64	Infectious complications in pediatric allogeneic hematopoietic stem cell transplantation recipients—A retrospective clinical and epidemiological cohort study. Transplant Infectious Disease, 2020, 22, e13369.	0.7	2
65	The challenge of longâ€ŧerm followâ€up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resourceâ€imited countries: A singleâ€center report from Brazil. Pediatric Transplantation, 2020, 24, e13691.	0.5	2
66	A case series of medicationâ€related fibrovascular hyperplasia following hematopoietic stem cell transplantation for Fanconi anemia. Pediatric Transplantation, 2021, 25, e13947.	0.5	2
67	IN TIME: IMPORTÃ,NCIA E IMPLICAÇÕES GLOBAIS DATRIAGEM NEONATAL PARA A IMUNODEFICIÊNCIA GRAVE COMBINADA. Revista Paulista De Pediatria, 2018, 36, 388-397.	0.4	2
68	Excelent Option Therapy of BONE Marrow Failure in Fanconi Anemia Patients Withouth Full Match Donnor. Blood, 2016, 128, 5075-5075.	0.6	2
69	Immune reconstitution after allogenic stem cell transplantation: An observational study in pediatric patients. Hematology, Transfusion and Cell Therapy, 2023, 45, 235-244.	0.1	2
70	Long Term Results of Allogeneic Stem Cell Transplant for CML in Pediatric Patients: A Study of 50 Cases Transplanted over 20 Years in a Single Institution Blood, 2006, 108, 5361-5361.	0.6	1
71	PERFIL CLÂNICO DE CRIAN‡AS SUBMETIDAS A TRANSPLANTE DE C‰LULAS-TRONCO HEMATOPOIÉTICAS. Cogitare Enfermagem, 0, 24, .	0.6	1
72	Elevated IgA and IL-10 levels in very-early-onset inflammatory bowel disease secondary to IL-10 receptor deficiency. Revista Paulista De Pediatria, 2021, 40, e2020434.	0.4	1

#	Article	IF	CITATIONS
73	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: children and adolescents. Einstein (Sao Paulo, Brazil), 2021, 19, eAE5254.	0.3	1
74	Nursing diagnosis after hematopoietic stem cell transplant due to Fanconi anemia. Revista Brasileira De Enfermagem, 2022, 75, e20190864.	0.2	1
75	COMPARATIVE ANALYSIS OF THE DATA ON THE INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE MARROW TRANSPLANTATION AND THE PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE 2020. Journal of Bone Marrow Transplantation and Cellular Therapy, 2020, 2, 63-68.	0.1	1
76	Treatment of 287 Patients(pts) with Severe Aplastic Anemia(SAA) Using Cyclosporine-A(Csa) and Prednisone(Pred): 15 Year Follow-Up from a Single Instituition Blood, 2004, 104, 2816-2816.	0.6	0
77	Unrelated Donor Stem Cell Transplantation for 36 Patients(pts) with Fanconi Anemia(FA): A Single Center Experience Blood, 2004, 104, 5171-5171.	0.6	О
78	Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia. Blood, 2010, 116, 213-213.	0.6	0
79	Allogeneic Stem Cell Transplantation for Sickle Cell Disease in Brazil: The Time Is Now!. Blood, 2011, 118, 1064-1064.	0.6	ο
80	Telomere Biology Gene Mutation and Transplant Outcome in Patients with Dyskeratosis Congenita. Blood, 2015, 126, 4785-4785.	0.6	0
81	Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts. Blood, 2015, 126, 4492-4492.	0.6	Ο
82	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis. Blood, 2016, 128, 842-842.	0.6	0
83	Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia. Blood, 2016, 128, 3575-3575.	0.6	Ο
84	HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age. Blood, 2016, 128, 4691-4691.	0.6	0
85	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. Hematology, Transfusion and Cell Therapy, 2021, 43, S13-S21.	0.1	0
86	Somatic mosaicism in patients with Fanconi anaemia: Proposal of alternative tissue for inconclusive diagnoses. International Journal of Laboratory Hematology, 0, , .	0.7	0